Top

Published in:

01-08-2010 | Review

Radiation-induced cell death mechanisms

Authors: David Eriksson, Torgny Stigbrand

Published in: Tumor Biology | Issue 4/2010

Abstract

The main goal when treating malignancies with radiation therapy is to deprive tumor cells of their reproductive potential. One approach to achieve this is by inducing tumor cell apoptosis. Accumulating evidences suggest that induction of apoptosis alone is insufficient to account for the therapeutic effect of radiotherapy. It has become obvious in the last few years that inhibition of the proliferative capacity of malignant cells following irradiation, especially with solid tumors, can occur via alternative cell death modalities or permanent cell cycle arrests, i.e., senescence. In this review, apoptosis and mitotic catastrophe, the two major cell deaths induced by radiation, are described and dissected in terms of activating mechanisms. Furthermore, treatment-induced senescence and its relevance for the outcome of radiotherapy of cancer will be discussed. The importance of p53 for the induction and execution of these different types of cell deaths is highlighted. The efficiency of radiotherapy and radioimmunotherapy has much to gain by understanding the cell death mechanisms that are induced in tumor cells following irradiation. Strategies to use specific inhibitors that will manipulate key molecules in these pathways in combination with radiation might potentiate therapy and enhance tumor cell kill.

Jonathan EC, Bernhard EJ, McKenna WG. How does radiation kill cells? Curr Opin Chem Biol. 1999;3:77–83.PubMed

Hollstein M, Sidransky D, Vogelstein B, Harris CC. P53 mutations in human cancers. Science. 1991;253:49–53.PubMed

Soussi T, Beroud C. Assessing tp53 status in human tumours to evaluate clinical outcome. Nat Rev Cancer. 2001;1:233–40.PubMed

Soussi T, Lozano G. P53 mutation heterogeneity in cancer. Biochem Biophys Res Commun. 2005;331:834–42.PubMed

Igney FH, Krammer PH. Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer. 2002;2:277–88.PubMed

Eriksson D, Riklund Ahlstrom K, Johansson L, Stigbrand T. Radiation induced cell deaths. In: Stigbrand T, Carlsson J, Adams G, editors. Targeted radionuclide tumor therapy—biological aspects. New York: Springer; 2008.

Gewirtz DA, Holt SE, Elmore LW. Accelerated senescence: an emerging role in tumor cell response to chemotherapy and radiation. Biochem Pharmacol. 2008;76:947–57.PubMed

Jones KR, Elmore LW, Jackson-Cook C, Demasters G, Povirk LF, Holt SE, et al. P53-dependent accelerated senescence induced by ionizing radiation in breast tumour cells. Int J Radiat Biol. 2005;81:445–58.PubMed

Lehmann BD, McCubrey JA, Jefferson HS, Paine MS, Chappell WH, Terrian DM. A dominant role for p53-dependent cellular senescence in radiosensitization of human prostate cancer cells. Cell Cycle. 2007;6:595–605.PubMed

10.

Ianzini F, Bertoldo A, Kosmacek EA, Phillips SL, Mackey MA. Lack of p53 function promotes radiation-induced mitotic catastrophe in mouse embryonic fibroblast cells. Cancer Cell Int. 2006;6:11.PubMed

11.

Efeyan A, Serrano M. P53: Guardian of the genome and policeman of the oncogenes. Cell Cycle. 2007;6:1006–10.PubMed

12.

Gottlieb TM, Oren M. P53 in growth control and neoplasia. Biochim Biophys Acta. 1996;1287:77–102.PubMed

13.

Lane DP. Cancer. P53, guardian of the genome. Nature. 1992;358:15–6.PubMed

14.

Marx J. Oncology. Recruiting the cell's own guardian for cancer therapy. Science. 2007;315:1211–3.PubMed

15.

Rodier F, Campisi J, Bhaumik D. Two faces of p53: aging and tumor suppression. Nucleic Acids Res. 2007;35:7475–84.PubMed

16.

Teodoro JG, Evans SK, Green MR. Inhibition of tumor angiogenesis by p53: a new role for the guardian of the genome. J Mol Med. 2007;85:1175–86.PubMed

17.

Helton ES, Chen X. P53 modulation of the DNA damage response. J Cell Biochem. 2007;100:883–96.PubMed

18.

Aylon Y, Oren M. Living with p53, dying of p53. Cell. 2007;130:597–600.PubMed

19.

Gudkov AV, Komarova EA. The role of p53 in determining sensitivity to radiotherapy. Nat Rev Cancer. 2003;3:117–29.PubMed

20.

Harris SL, Levine AJ. The p53 pathway: positive and negative feedback loops. Oncogene. 2005;24:2899–908.PubMed

21.

Laptenko O, Prives C. Transcriptional regulation by p53: one protein, many possibilities. Cell Death Differ. 2006;13:951–61.PubMed

22.

Liebermann DA, Hoffman B, Vesely D. P53 induced growth arrest versus apoptosis and its modulation by survival cytokines. Cell Cycle. 2007;6:166–70.PubMed

23.

Das S, Boswell SA, Aaronson SA, Lee SW. P53 promoter selection: choosing between life and death. Cell Cycle. 2008;7:154–7.PubMed

24.

Das S, Raj L, Zhao B, Kimura Y, Bernstein A, Aaronson SA, et al. Hzf determines cell survival upon genotoxic stress by modulating p53 transactivation. Cell. 2007;130:624–37.PubMed

25.

Tanaka T, Ohkubo S, Tatsuno I, Prives C. Hcas/cse1l associates with chromatin and regulates expression of select p53 target genes. Cell. 2007;130:638–50.PubMed

26.

Erenpreisa J, Cragg MS. Cancer: a matter of life cycle? Cell Biol Int. 2007;31:1507–10.PubMed

27.

Ganem NJ, Pellman D. Limiting the proliferation of polyploid cells. Cell. 2007;131:437–40.PubMed

28.

Ganem NJ, Storchova Z, Pellman D. Tetraploidy, aneuploidy and cancer. Curr Opin Genet Dev. 2007;17:157–62.PubMed

29.

Storchova Z, Pellman D. From polyploidy to aneuploidy, genome instability and cancer. Nat Rev Mol Cell Biol. 2004;5:45–54.PubMed

30.

Dewey WC, Ling CC, Meyn RE. Radiation-induced apoptosis: relevance to radiotherapy. Int J Radiat Oncol Biol Phys. 1995;33:781–96.PubMed

31.

Verheij M, Bartelink H. Radiation-induced apoptosis. Cell Tissue Res. 2000;301:133–42.PubMed

32.

Radford IR, Murphy TK, Radley JM, Ellis SL. Radiation response of mouse lymphoid and myeloid cell lines. Part ii. Apoptotic death is shown by all lines examined. Int J Radiat Biol. 1994;65:217–27.PubMed

33.

Shinomiya N. New concepts in radiation-induced apoptosis: 'premitotic apoptosis' and 'postmitotic apoptosis'. J Cell Mol Med. 2001;5:240–53.PubMed

34.

Clarke AR, Purdie CA, Harrison DJ, Morris RG, Bird CC, Hooper ML, et al. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature. 1993;362:849–52.PubMed

35.

Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T. P53 is required for radiation-induced apoptosis in mouse thymocytes. Nature. 1993;362:847–9.PubMed

36.

Riedl SJ, Shi Y. Molecular mechanisms of caspase regulation during apoptosis. Nat Rev Mol Cell Biol. 2004;5:897–907.PubMed

37.

Timmer JC, Salvesen GS. Caspase substrates. Cell Death Differ. 2007;14:66–72.PubMed

38.

Jin Z, El-Deiry WS. Overview of cell death signaling pathways. Cancer Biol Ther. 2005;4:139–63.PubMedCrossRef

39.

Alvarez S, Drane P, Meiller A, Bras M, Deguin-Chambon V, Bouvard V, et al. A comprehensive study of p53 transcriptional activity in thymus and spleen of gamma irradiated mouse: high sensitivity of genes involved in the two main apoptotic pathways. Int J Radiat Biol. 2006;82:761–70.PubMed

40.

Findley HW, Gu L, Yeager AM, Zhou M. Expression and regulation of bcl-2, bcl-xl, and bax correlate with p53 status and sensitivity to apoptosis in childhood acute lymphoblastic leukemia. Blood. 1997;89:2986–93.PubMed

41.

Kobayashi T, Ruan S, Jabbur JR, Consoli U, Clodi K, Shiku H, et al. Differential p53 phosphorylation and activation of apoptosis-promoting genes bax and fas/apo-1 by irradiation and ara-c treatment. Cell Death Differ. 1998;5:584–91.PubMed

42.

Zhan Q, Fan S, Bae I, Guillouf C, Liebermann DA, O'Connor PM, et al. Induction of bax by genotoxic stress in human cells correlates with normal p53 status and apoptosis. Oncogene. 1994;9:3743–51.PubMed

43.

Erlacher M, Michalak EM, Kelly PN, Labi V, Niederegger H, Coultas L, et al. Bh3-only proteins puma and bim are rate-limiting for gamma-radiation- and glucocorticoid-induced apoptosis of lymphoid cells in vivo. Blood. 2005;106:4131–8.PubMed

44.

Michalak EM, Villunger A, Adams JM, Strasser A. In several cell types tumour suppressor p53 induces apoptosis largely via puma but noxa can contribute. Cell Death Differ. 2008;15:1019–29.PubMed

45.

Jeffers JR, Parganas E, Lee Y, Yang C, Wang J, Brennan J, et al. Puma is an essential mediator of p53-dependent and -independent apoptotic pathways. Cancer Cell. 2003;4:321–8.PubMed

46.

Villunger A, Michalak EM, Coultas L, Mullauer F, Bock G, Ausserlechner MJ, et al. P53- and drug-induced apoptotic responses mediated by bh3-only proteins puma and noxa. Science. 2003;302:1036–8.PubMed

47.

Lin Y, Ma W, Benchimol S. Pidd, a new death-domain-containing protein, is induced by p53 and promotes apoptosis. Nat Genet. 2000;26:122–7.PubMed

48.

Fei P, El-Deiry WS. P53 and radiation responses. Oncogene. 2003;22:5774–83.PubMed

49.

Haldar S, Negrini M, Monne M, Sabbioni S, Croce CM. Down-regulation of bcl-2 by p53 in breast cancer cells. Cancer Res. 1994;54:2095–7.PubMed

50.

Miyashita T, Harigai M, Hanada M, Reed JC. Identification of a p53-dependent negative response element in the bcl-2 gene. Cancer Res. 1994;54:3131–5.PubMed

51.

Hoffman WH, Biade S, Zilfou JT, Chen J, Murphy M. Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem. 2002;277:3247–57.PubMed

52.

Zhou M, Gu L, Li F, Zhu Y, Woods WG, Findley HW. DNA damage induces a novel p53-survivin signaling pathway regulating cell cycle and apoptosis in acute lymphoblastic leukemia cells. J Pharmacol Exp Ther. 2002;303:124–31.PubMed

53.

Wang X. The expanding role of mitochondria in apoptosis. Genes Dev. 2001;15:2922–33.PubMed

54.

Jiang X, Wang X. Cytochrome c promotes caspase-9 activation by inducing nucleotide binding to apaf-1. J Biol Chem. 2000;275:31199–203.PubMed

55.

Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES, et al. Cytochrome c and datp-dependent formation of apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell. 1997;91:479–89.PubMed

56.

Rodriguez J, Lazebnik Y. Caspase-9 and apaf-1 form an active holoenzyme. Genes Dev. 1999;13:3179–84.PubMed

57.

Embree-Ku M, Venturini D, Boekelheide K. Fas is involved in the p53-dependent apoptotic response to ionizing radiation in mouse testis. Biol Reprod. 2002;66:1456–61.PubMed

58.

Sheard MA, Uldrijan S, Vojtesek B. Role of p53 in regulating constitutive and x-radiation-inducible cd95 expression and function in carcinoma cells. Cancer Res. 2003;63:7176–84.PubMed

59.

Sheard MA, Vojtesek B, Janakova L, Kovarik J, Zaloudik J. Up-regulation of fas (cd95) in human p53wild-type cancer cells treated with ionizing radiation. Int J Cancer. 1997;73:757–62.PubMed

60.

Burns TF, Bernhard EJ, El-Deiry WS. Tissue specific expression of p53 target genes suggests a key role for killer/dr5 in p53-dependent apoptosis in vivo. Oncogene. 2001;20:4601–12.PubMed

61.

Sheikh MS, Burns TF, Huang Y, Wu GS, Amundson S, Brooks KS, et al. P53-dependent and -independent regulation of the death receptor killer/dr5 gene expression in response to genotoxic stress and tumor necrosis factor alpha. Cancer Res. 1998;58:1593–8.PubMed

62.

Wu GS, Burns TF, McDonald 3rd ER, Jiang W, Meng R, Krantz ID, et al. Killer/dr5 is a DNA damage-inducible p53-regulated death receptor gene. Nat Genet. 1997;17:141–3.PubMed

63.

Kastan M. On the trail from p53 to apoptosis? Nat Genet. 1997;17:130–1.PubMed

64.

Scaffidi C, Fulda S, Srinivasan A, Friesen C, Li F, Tomaselli KJ, et al. Two cd95 (apo-1/fas) signaling pathways. EMBO J. 1998;17:1675–87.PubMed

65.

Taylor RC, Cullen SP, Martin SJ. Apoptosis: controlled demolition at the cellular level. Nat Rev Mol Cell Biol. 2007;9:231–41.

66.

Luo X, Budihardjo I, Zou H, Slaughter C, Wang X. Bid, a bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell. 1998;94:481–90.PubMed

67.

Galluzzi L, Maiuri MC, Vitale I, Zischka H, Castedo M, Zitvogel L, et al. Cell death modalities: Classification and pathophysiological implications. Cell Death Differ. 2007;14:1237–43.PubMed

68.

Roninson IB, Broude EV, Chang BD. If not apoptosis, then what? Treatment-induced senescence and mitotic catastrophe in tumor cells. Drug Resist Updat. 2001;4:303–13.PubMed

69.

Bhattathiri NV, Bharathykkutty C, Prathapan R, Chirayathmanjiyil DA, Nair KM. Prediction of radiosensitivity of oral cancers by serial cytological assay of nuclear changes. Radiother Oncol. 1998;49:61–5.PubMed

70.

Bhattathiri NV, Bindu L, Remani P, Chandralekha B, Nair KM. Radiation-induced acute immediate nuclear abnormalities in oral cancer cells: serial cytologic evaluation. Acta Cytol. 1998;42:1084–90.PubMed

71.

Eriksson D, Joniani HM, Sheikholvaezin A, Lofroth PO, Johansson L. Combined low dose radio- and radioimmunotherapy of experimental hela hep 2 tumours. Eur J Nucl Med Mol Imaging. 2003;30:895–906.PubMed

72.

Eriksson D, Lofroth PO, Johansson L, Riklund KA, Stigbrand T. Cell cycle disturbances and mitotic catastrophes in hela hep2 cells following 2.5 to 10 gy of ionizing radiation. Clin Cancer Res. 2007;13:5501s–8.PubMed

73.

Somosy Z. Radiation response of cell organelles. Micron. 2000;31:165–81.PubMed

74.

Castedo M, Kroemer G. [mitotic catastrophe: a special case of apoptosis]. J Soc Biol. 2004;198:97–103.PubMed

75.

Erenpreisa J, Kalejs M, Ianzini F, Kosmacek EA, Mackey MA, Emzinsh D, et al. Segregation of genomes in polyploid tumour cells following mitotic catastrophe. Cell Biol Int. 2005;29:1005–11.PubMed

76.

Bourke E, Dodson H, Merdes A, Cuffe L, Zachos G, Walker M, et al. DNA damage induces chk1-dependent centrosome amplification. EMBO Rep. 2007;8:603–9.PubMed

77.

Dodson H, Wheatley SP, Morrison CG. Involvement of centrosome amplification in radiation-induced mitotic catastrophe. Cell Cycle. 2007;6:364–70.PubMed

78.

Kawamura K, Fujikawa-Yamamoto K, Ozaki M, Iwabuchi K, Nakashima H, Domiki C, et al. Centrosome hyperamplification and chromosomal damage after exposure to radiation. Oncology. 2004;67:460–70.PubMed

79.

Kawamura K, Morita N, Domiki C, Fujikawa-Yamamoto K, Hashimoto M, Iwabuchi K, et al. Induction of centrosome amplification in p53 sirna-treated human fibroblast cells by radiation exposure. Cancer Sci. 2006;97:252–8.PubMed

80.

Eriksson D, Lofroth PO, Johansson L, Riklund K, Stigbrand T. Apoptotic signalling in hela hep2 cells following 5 gy of cobalt-60 gamma radiation. Anticancer Res. 2009;29:4361–6.PubMed

81.

Loffler H, Lukas J, Bartek J, Kramer A. Structure meets function–centrosomes, genome maintenance and the DNA damage response. Exp Cell Res. 2006;312:2633–40.PubMed

82.

Eriksson D, Blomberg J, Lindgren T, Lofroth PO, Johansson L, Riklund K, et al. Iodine-131 induces mitotic catastrophes and activates apoptotic pathways in hela hep2 cells. Cancer Biother Radiopharm. 2008;23:541–9.PubMed

83.

Wang Y, Ji P, Liu J, Broaddus RR, Xue F, Zhang W. Centrosome-associated regulators of the g(2)/m checkpoint as targets for cancer therapy. Mol Cancer. 2009;8:8.PubMed

84.

Castedo M, Perfettini JL, Roumier T, Andreau K, Medema R, Kroemer G. Cell death by mitotic catastrophe: a molecular definition. Oncogene. 2004;23:2825–37.PubMed

85.

Hanashiro K, Kanai M, Geng Y, Sicinski P, Fukasawa K. Roles of cyclins a and e in induction of centrosome amplification in p53-compromised cells. Oncogene. 2008;27:5288–302.PubMed

86.

Fukasawa K. Oncogenes and tumour suppressors take on centrosomes. Nat Rev Cancer. 2007;7:911–24.PubMed

87.

Fukasawa K. P53, cyclin-dependent kinase and abnormal amplification of centrosomes. Biochim Biophys Acta. 2008;1786:15–23.PubMed

88.

Castedo M, Perfettini JL, Roumier T, Valent A, Raslova H, Yakushijin K, et al. Mitotic catastrophe constitutes a special case of apoptosis whose suppression entails aneuploidy. Oncogene. 2004;23:4362–70.PubMed

89.

Abend M. Reasons to reconsider the significance of apoptosis for cancer therapy. Int J Radiat Biol. 2003;79:927–41.PubMed

90.

Ruth AC, Roninson IB. Effects of the multidrug transporter p-glycoprotein on cellular responses to ionizing radiation. Cancer Res. 2000;60:2576–8.PubMed

91.

Jallepalli PV, Lengauer C. Chromosome segregation and cancer: cutting through the mystery. Nat Rev Cancer. 2001;1:109–17.PubMed

92.

Norbury CJ, Zhivotovsky B. DNA damage-induced apoptosis. Oncogene. 2004;23:2797–808.PubMed

93.

Zhivotovsky B, Orrenius S. Caspase-2 function in response to DNA damage. Biochem Biophys Res Commun. 2005;331:859–67.PubMed

94.

Weaver BA, Cleveland DW. Decoding the links between mitosis, cancer, and chemotherapy: the mitotic checkpoint, adaptation, and cell death. Cancer Cell. 2005;8:7–12.PubMed

95.

Yamada HY, Gorbsky GJ. Spindle checkpoint function and cellular sensitivity to antimitotic drugs. Mol Cancer Ther. 2006;5:2963–9.PubMed

96.

Rieder CL, Maiato H. Stuck in division or passing through: What happens when cells cannot satisfy the spindle assembly checkpoint. Dev Cell. 2004;7:637–51.PubMed

97.

Castedo M, Coquelle A, Vivet S, Vitale I, Kauffmann A, Dessen P, et al. Apoptosis regulation in tetraploid cancer cells. EMBO J. 2006;25:2584–95.PubMed

98.

Uetake Y, Sluder G. Cell cycle progression after cleavage failure: mammalian somatic cells do not possess a "Tetraploidy checkpoint". J Cell Biol. 2004;165:609–15.PubMed

99.

Blagosklonny MV, Demidenko ZN, Giovino M, Szynal C, Donskoy E, Herrmann RA, et al. Cytostatic activity of paclitaxel in coronary artery smooth muscle cells is mediated through transient mitotic arrest followed by permanent post-mitotic arrest: comparison with cancer cells. Cell Cycle. 2006;5:1574–9.PubMed

100.

Klein LE, Freeze BS, Smith 3rd AB, Horwitz SB. The microtubule stabilizing agent discodermolide is a potent inducer of accelerated cell senescence. Cell Cycle. 2005;4:501–7.PubMed

101.

Casenghi M, Mangiacasale R, Tuynder M, Caillet-Fauquet P, Elhajouji A, Lavia P, et al. P53-independent apoptosis and p53-dependent block of DNA rereplication following mitotic spindle inhibition in human cells. Exp Cell Res. 1999;250:339–50.PubMed

102.

Chang BD, Broude EV, Dokmanovic M, Zhu H, Ruth A, Xuan Y, et al. A senescence-like phenotype distinguishes tumor cells that undergo terminal proliferation arrest after exposure to anticancer agents. Cancer Res. 1999;59:3761–7.PubMed

103.

Chang BD, Swift ME, Shen M, Fang J, Broude EV, Roninson IB. Molecular determinants of terminal growth arrest induced in tumor cells by a chemotherapeutic agent. Proc Natl Acad Sci U S A. 2002;99:389–94.PubMed

104.

Elmore LW, Rehder CW, Di X, McChesney PA, Jackson-Cook CK, Gewirtz DA, et al. Adriamycin-induced senescence in breast tumor cells involves functional p53 and telomere dysfunction. J Biol Chem. 2002;277:35509–15.PubMed

105.

Han Z, Wei W, Dunaway S, Darnowski JW, Calabresi P, Sedivy J, et al. Role of p21 in apoptosis and senescence of human colon cancer cells treated with camptothecin. J Biol Chem. 2002;277:17154–60.PubMed

106.

Haq R, Brenton JD, Takahashi M, Finan D, Finkielsztein A, Damaraju S, et al. Constitutive p38hog mitogen-activated protein kinase activation induces permanent cell cycle arrest and senescence. Cancer Res. 2002;62:5076–82.PubMed

107.

Mirzayans R, Scott A, Cameron M, Murray D. Induction of accelerated senescence by gamma radiation in human solid tumor-derived cell lines expressing wild-type tp53. Radiat Res. 2005;163:53–62.PubMed

108.

Quick QA, Gewirtz DA. An accelerated senescence response to radiation in wild-type p53 glioblastoma multiforme cells. J Neurosurg. 2006;105:111–8.PubMed

109.

Roberson RS, Kussick SJ, Vallieres E, Chen SY, Wu DY. Escape from therapy-induced accelerated cellular senescence in p53-null lung cancer cells and in human lung cancers. Cancer Res. 2005;65:2795–803.PubMed

110.

Roninson IB. Tumor cell senescence in cancer treatment. Cancer Res. 2003;63:2705–15.PubMed

111.

Schmitt CA. Cellular senescence and cancer treatment. Biochim Biophys Acta. 2007;1775:5–20.PubMed

112.

Schmitt CA, Fridman JS, Yang M, Lee S, Baranov E, Hoffman RM, et al. A senescence program controlled by p53 and p16ink4a contributes to the outcome of cancer therapy. Cell. 2002;109:335–46.PubMed

113.

Schwarze SR, Fu VX, Desotelle JA, Kenowski ML, Jarrard DF. The identification of senescence-specific genes during the induction of senescence in prostate cancer cells. Neoplasia. 2005;7:816–23.PubMed

114.

te Poele RH, Okorokov AL, Jardine L, Cummings J, Joel SP. DNA damage is able to induce senescence in tumor cells in vitro and in vivo. Cancer Res. 2002;62:1876–83.

115.

Bataini JP, Belloir C, Mazabraud A, Pilleron JP, Cartigny A, Jaulerry C, et al. Desmoid tumors in adults: The role of radiotherapy in their management. Am J Surg. 1988;155:754–60.PubMed

116.

Cox JD, Kline RW. Do prostatic biopsies 12 months or more after external irradiation for adenocarcinoma, stage iii, predict long-term survival? Int J Radiat Oncol Biol Phys. 1983;9:299–303.PubMed

117.

Shay JW, Roninson IB. Hallmarks of senescence in carcinogenesis and cancer therapy. Oncogene. 2004;23:2919–33.PubMed

118.

Deng Y, Chan SS, Chang S. Telomere dysfunction and tumour suppression: The senescence connection. Nat Rev Cancer. 2008;8:450–8.PubMed

119.

Hayflick L, Moorhead PS. The serial cultivation of human diploid cell strains. Exp Cell Res. 1961;25:585–621.

120.

Stein GH, Dulic V. Origins of g1 arrest in senescent human fibroblasts. Bioessays. 1995;17:537–43.PubMed

121.

Collado M, Serrano M. Senescence in tumours: evidence from mice and humans. Nat Rev Cancer. 2010;10:51–7.PubMed

122.

Rodier F, Coppe JP, Patil CK, Hoeijmakers WA, Munoz DP, Raza SR, et al. Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion. Nat Cell Biol. 2009;11:973–9.PubMed

123.

Suzuki K, Mori I, Nakayama Y, Miyakoda M, Kodama S, Watanabe M. Radiation-induced senescence-like growth arrest requires tp53 function but not telomere shortening. Radiat Res. 2001;155:248–53.PubMed

124.

Dai CY, Enders GH. P16 ink4a can initiate an autonomous senescence program. Oncogene. 2000;19:1613–22.PubMed

125.

Steiner MS, Wang Y, Zhang Y, Zhang X, Lu Y. P16/mts1/ink4a suppresses prostate cancer by both prb dependent and independent pathways. Oncogene. 2000;19:1297–306.PubMed

126.

Sugrue MM, Shin DY, Lee SW, Aaronson SA. Wild-type p53 triggers a rapid senescence program in human tumor cells lacking functional p53. Proc Natl Acad Sci U S A. 1997;94:9648–53.PubMed

127.

Zhang H. Molecular signaling and genetic pathways of senescence: its role in tumorigenesis and aging. J Cell Physiol. 2007;210:567–74.PubMed

128.

Coppe JP, Desprez PY, Krtolica A, Campisi J. The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu Rev Pathol. 2010;5:99–118.PubMed

129.

Novakova Z, Hubackova S, Kosar M, Janderova-Rossmeislova L, Dobrovolna J, Vasicova P, et al. Cytokine expression and signaling in drug-induced cellular senescence. Oncogene. 2010;29:273–84.PubMed

130.

Xue W, Zender L, Miething C, Dickins RA, Hernando E, Krizhanovsky V, et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature. 2007;445:656–60.PubMed

131.

Bassett EA, Wang W, Rastinejad F, El-Deiry WS. Structural and functional basis for therapeutic modulation of p53 signaling. Clin Cancer Res. 2008;14:6376–86.PubMed

132.

Brown CJ, Lain S, Verma CS, Fersht AR, Lane DP. Awakening guardian angels: drugging the p53 pathway. Nat Rev Cancer. 2009;9:862–73.PubMed

133.

Wang W, El-Deiry WS. Restoration of p53 to limit tumor growth. Curr Opin Oncol. 2008;20:90–6.PubMed

134.

Wiman KG. Restoration of wild-type p53 function in human tumors: Strategies for efficient cancer therapy. Adv Cancer Res. 2007;97:321–38.PubMed

135.

Kawabe T. G2 checkpoint abrogators as anticancer drugs. Mol Cancer Ther. 2004;3:513–9.PubMed

136.

Lapenna S, Giordano A. Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009;8:547–66.PubMed

137.

Gautschi O, Heighway J, Mack PC, Purnell PR, Lara Jr PN, Gandara DR. Aurora kinases as anticancer drug targets. Clin Cancer Res. 2008;14:1639–48.PubMed

138.

Kitzen JJ, de Jonge MJ, Verweij J. Aurora kinase inhibitors. Crit Rev Oncol Hematol. 2010;73:99–110.PubMed

139.

Mita AC, Mita MM, Nawrocki ST, Giles FJ. Survivin: Key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res. 2008;14:5000–5.PubMed

140.

Kwon M, Godinho SA, Chandhok NS, Ganem NJ, Azioune A, Thery M, et al. Mechanisms to suppress multipolar divisions in cancer cells with extra centrosomes. Genes Dev. 2008;22:2189–203.PubMed

141.

Rello-Varona S, Vitale I, Kepp O, Senovilla L, Jemaa M, Metivier D, et al. Preferential killing of tetraploid tumor cells by targeting the mitotic kinesin eg5. Cell Cycle. 2009;8:1030–5.PubMed

Title: Radiation-induced cell death mechanisms
Authors: David Eriksson
Torgny Stigbrand
Publication date: 01-08-2010
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 4/2010
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-010-0042-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2010

Galectin-3 expression is associated with bladder cancer progression and clinical outcome

CpG island methylator phenotype of multigene in serum of sporadic breast carcinoma

Emerging strategies for the identification and targeting of cancer stem cells

Disruption of p73-MDM2 binding synergizes with gemcitabine to induce apoptosis in HuCCT1 cholangiocarcinoma cell line with p53 mutation

Predictors of sensitivity to chemoradiotherapy of esophageal squamous cell carcinoma

Impact of pretreatment hematologic profile on survival of colorectal cancer patients

Keynote webinar | Spotlight on antibody–drug conjugates in cancer